| __timestamp | CymaBay Therapeutics, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 8185000 | 612613000000 |
| Thursday, January 1, 2015 | 8871000 | 650773000000 |
| Friday, January 1, 2016 | 9645000 | 619061000000 |
| Sunday, January 1, 2017 | 12387000 | 628106000000 |
| Monday, January 1, 2018 | 14381000 | 717599000000 |
| Tuesday, January 1, 2019 | 19238000 | 964737000000 |
| Wednesday, January 1, 2020 | 17425000 | 875663000000 |
| Friday, January 1, 2021 | 23040000 | 886361000000 |
| Saturday, January 1, 2022 | 25116000 | 997309000000 |
| Sunday, January 1, 2023 | 51953000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Unveiling the hidden dimensions of data
In the competitive world of pharmaceuticals, managing costs is crucial. This chart compares the Selling, General, and Administrative (SG&A) expenses of Takeda Pharmaceutical Company Limited and CymaBay Therapeutics, Inc. from 2014 to 2023. Takeda, a global leader, consistently shows SG&A expenses in the hundreds of billions, peaking at approximately 1.05 trillion in 2023. In contrast, CymaBay, a smaller player, saw its expenses grow from around 8 million in 2014 to over 51 million in 2023, marking a staggering 525% increase. This stark contrast highlights the scale and operational differences between a pharmaceutical giant and a nimble biotech firm. Notably, data for CymaBay in 2024 is missing, indicating potential reporting delays or strategic shifts. Such insights are invaluable for investors and industry analysts seeking to understand cost management strategies in the pharmaceutical sector.
Comparing SG&A Expenses: AstraZeneca PLC vs CymaBay Therapeutics, Inc. Trends and Insights
Selling, General, and Administrative Costs: Sanofi vs CymaBay Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Ligand Pharmaceuticals Incorporated Trends and Insights
BeiGene, Ltd. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or ImmunityBio, Inc.
Cost Management Insights: SG&A Expenses for CymaBay Therapeutics, Inc. and MannKind Corporation
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Evotec SE